PTCH1 and cancer: The most common mutations in these tumors include loss-of-function mutations in PTCH and SUFU, gain-of-function mutation in SMO, or gene amplifications in GLI1 and GLI2, as shown in mouse or human cancers, resulting in uncontrolled Hh activity and promoting tumorigenesis (57, 58).